VPM1002BCBackground:VPM1002BC is a genetically modified Mycobacterium bovis bacillus Calmette-Gu茅rin (BCG) strain with potentially improved immunogenicity and attenuation. Objective:To report on the efficacy, safety, tolerability and quality of life of intravesical VPM1002BC for the treatment of non-...
Results of the phase-I open-label clinical trial SAKK 06/14 assessing safety of intravesical instillation of the recombinant BCG VPM1002BC in patients with non-muscle invasive bladder cancer and previous failure to conventional BCG therapyResults...